Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VRDN

Viridian Therapeutics Inc

Dec 13 • 04:00PM ET

17.85

Dollar change -0.14
Percentage change -0.78	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX EXEL SRPT BMRN ALNY RARE IONS ADAP PBYI

| Held by: VTI IWM VXF XBI IWO VTWO SCHA VHT IWN IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.31	Insider Own	11.04%	Shs Outstand	79.18M	Perf Week	-9.48%
Market Cap	1.40B	Forward P/E	-	EPS next Y	-4.15	Insider Trans	22.85%	Shs Float	70.47M	Perf Month	-20.60%
Income	-257.08M	PEG	-	EPS next Q	-1.03	Inst Own	98.98%	Short Float	12.42%	Perf Quarter	-17.21%
Sales	0.30M	P/S	4676.49	EPS this Y	24.09%	Inst Trans	22.50%	Short Ratio	7.76	Perf Half Y	43.49%
Book/sh	6.55	P/B	2.73	EPS next Y	-2.98%	ROA	-46.71%	Short Interest	8.75M	Perf Year	-7.18%
Cash/sh	9.58	P/C	1.86	EPS next 5Y	-	ROE	-51.88%	52W Range	11.40 - 27.20	Perf YTD	-18.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.35%	ROI	-35.21%	52W High	-34.38%	Beta	1.12
Dividend TTM	-	Quick Ratio	18.55	Sales past 5Y	-12.71%	Gross Margin	-418.87%	52W Low	56.58%	ATR (14)	1.00
Dividend Ex-Date	-	Current Ratio	18.55	EPS Y/Y TTM	15.56%	Oper. Margin	-93722.85%	RSI (14)	28.90	Volatility	3.95% 4.93%
Employees	96	Debt/Eq	0.03	Sales Y/Y TTM	-12.97%	Profit Margin	-85127.15%	Recom	1.12	Target Price	40.62
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-5.75%	Payout	-	Rel Volume	1.37	Prev Close	17.99
Sales Surprise	1.30%	EPS Surprise	-8.77%	Sales Q/Q	19.44%	Earnings	Nov 12 BMO	Avg Volume	1.13M	Price	17.85
SMA20	-10.93%	SMA50	-19.14%	SMA200	3.27%	Trades		Volume	1,549,312	Change	-0.78%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy	$30 → $38
Jun-11-24	Initiated	Wolfe Research	Outperform	$29
Jun-06-24	Initiated	Goldman	Buy	$23
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral	$25 → $20
Jun-14-23	Resumed	Credit Suisse	Outperform	$51
Jun-14-23	Initiated	BTIG Research	Buy	$46
May-30-23	Initiated	RBC Capital Mkts	Outperform	$44
Apr-17-23	Initiated	Wells Fargo	Overweight	$46
Mar-30-23	Initiated	Stifel	Buy	$49
Dec-19-22	Initiated	Needham	Buy	$45
Dec-19-22	Initiated	Cowen	Outperform	$45
Dec-16-22	Initiated	Credit Suisse	Outperform	$51
Dec-01-22	Initiated	H.C. Wainwright	Buy	$35
Jun-23-22	Initiated	B. Riley Securities	Buy	$25
Nov-18-21	Initiated	SVB Leerink	Outperform	$32
Oct-12-21	Initiated	Evercore ISI	Outperform	$40
Jan-25-21	Initiated	Ladenburg Thalmann	Buy	$40

Show Previous Ratings

Dec-13-24 06:00PM	Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 (Business Wire)
Dec-04-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-24 07:00AM	Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data (Business Wire) -12.76%
Nov-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-24 11:25PM	Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock (Business Wire) +5.60%
04:01PM	Loading…
Sep-10-24 04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire) +32.14%
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (Business Wire)
Sep-09-24 04:01PM	Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 (Business Wire)
Sep-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.23%
Aug-08-24 08:15AM	Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-07-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-24 09:09AM	Goldman Sachs Predicts up to 165% Surge for These 2 Strong Buy Stocks (TipRanks)
Jul-25-24 08:00AM	Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire)
Jul-08-24 10:38AM	3 Small-Cap Stocks With Explosive 2X Growth Potential (InvestorPlace)
Jul-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:48AM	Loading…
Jun-27-24 09:48AM	Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-12-24 09:11AM	Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug (Zacks) -5.94%
Jun-11-24 06:00AM	Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease (Business Wire) +10.15%
Jun-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-31-24 08:00AM	Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences (Business Wire)
May-10-24 08:00AM	Viridian Therapeutics to Participate in Upcoming May Investor Conferences (Business Wire)
May-09-24 03:02AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com) -6.64%
May-08-24 11:54AM	VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:36AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements (GuruFocus.com)
08:25AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results (Business Wire)
May-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.62%
Apr-29-24 08:00AM	Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 (Business Wire) +5.59%
Apr-04-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:01PM	Loading…
Mar-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-24 08:00AM	Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (Business Wire)
Feb-28-24 09:55AM	How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81% (Zacks)
Feb-27-24 04:01PM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-16-24 08:00AM	Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer (Business Wire)
Feb-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-17-24 10:00PM	Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock (Business Wire) -9.73%
04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire)
Jan-08-24 08:00AM	Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference (Business Wire) +7.78%
Jan-04-24 08:00AM	Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-23 07:00AM	Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease (Business Wire) +9.52%
Nov-21-23 08:00AM	Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 05:00PM	Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com) +8.79%
04:01PM	Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Nov-08-23 08:00AM	Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-03-23 08:00AM	Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology (Business Wire) +7.88%
Oct-30-23 08:30AM	Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing (Business Wire) +5.17%
Oct-26-23 08:00AM	Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease (Business Wire) +8.57%
Sep-25-23 08:00AM	Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors (Business Wire)
Sep-07-23 08:00AM	Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September (Business Wire)
Aug-08-23 04:01PM	Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire) +5.69%
Aug-04-23 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jul-10-23 04:01PM	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire) +5.06% -16.39%
Jul-06-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jun-13-23 08:00AM	Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society (Business Wire)
Jun-05-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-23 04:01PM	Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 08:00AM	Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections (GlobeNewswire)
May-04-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-23 08:00AM	Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023 (GlobeNewswire)
Apr-20-23 01:41PM	UPDATE Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (GlobeNewswire)
08:00AM	Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (GlobeNewswire)
Apr-16-23 09:50AM	TipRanks Perfect 10 List: 2 Top-Rated Stocks Potentially Undervalued by ~90% (TipRanks)
Apr-13-23 06:52AM	Daily Vickers Top Buyers & Sellers for 04/13/2023 (Argus Research)
Apr-12-23 08:00AM	Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer (GlobeNewswire)
Apr-04-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-08-23 07:00AM	Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates (GlobeNewswire) -10.48%
Mar-07-23 08:00AM	Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (GlobeNewswire)
Mar-03-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-23 08:00AM	Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023 (GlobeNewswire)
Feb-28-23 08:00AM	Viridian Therapeutics to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 08:00AM	Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference (GlobeNewswire)
Feb-06-23 07:00AM	Viridian Appoints Scott Myers as President and Chief Executive Officer (GlobeNewswire)
Feb-02-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-08-23 08:00AM	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) (GlobeNewswire)
Jan-05-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-03-23 08:00AM	Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 07:00AM	Viridian Therapeutics Announces First Patient Enrolled in the THRIVE Phase 3 Trial in Patients With Thyroid Eye Disease (GlobeNewswire) +7.34%
Dec-07-22 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-28-22 07:00AM	Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-16-22 05:10AM	Viridian Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-14-22 07:01AM	Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates (GlobeNewswire)
06:59AM	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) (GlobeNewswire)
Nov-08-22 07:05AM	Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th (GlobeNewswire)
07:00AM	Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022 (GlobeNewswire)
Oct-22-22 02:04PM	Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting (GlobeNewswire)
Oct-12-22 08:12AM	Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting (GlobeNewswire)
Sep-02-22 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-31-22 08:00AM	Why Viridian's CEO Isn't Sweating His Company's Second-Place Position (Investor's Business Daily)
Aug-25-22 04:03PM	Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters Option to Purchase Additional Shares in Public Offering (GlobeNewswire)
Aug-17-22 08:59AM	Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet? (Simply Wall St.) -10.67%
06:00AM	Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock (GlobeNewswire)
Aug-15-22 04:35PM	New Contender Viridian Takes Aim At Horizon's Eye Drug, And Rockets (Investor's Business Daily) +49.36% +15.91%
04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (GlobeNewswire)
02:17PM	Options Traders Blast Surging Biotech Stock After Earnings (Schaeffer's Investment Research)
07:02AM	Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates (GlobeNewswire)
06:59AM	Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) (GlobeNewswire)
Aug-08-22 08:00AM	Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022 (GlobeNewswire)
Aug-05-22 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-08-22 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Beetham Thomas W.	Chief Operating Officer	Sep 27 '24	Buy	23.41	5,000	117,050	6,000	Sep 30 07:12 PM
Mahoney Stephen F.	President and CEO	Sep 27 '24	Buy	23.33	21,400	499,262	21,400	Sep 30 07:10 PM
Fairmount Funds Management LLC	Director	Sep 13 '24	Buy	18.75	1,600,000	30,000,000	3,445,813	Sep 17 09:00 PM
Fairmount Funds Management LLC	Director	Jan 22 '24	Buy	21.00	476,190	9,999,990	1,839,954	Jan 24 06:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRDN

Viridian Therapeutics Inc

Upgrade your FINVIZ experience